DashboardAll companies
Run this on your own research
Healthcare · Drug Manufacturers - General

Eli Lilly and Company

LLYNYSE$1,273.46−$33.23 (−2.54%)Market closed

Price Chart

Daily

Key facts

Market Cap
$1.14T
P/E
55.2x
P/B
42.94x
ROE
101.4%

Eli Lilly and Company

Healthcare · Drug Manufacturers - General · FY 2025

Eli Lilly and Company is a leading pharmaceutical firm with a global reputation for developing and marketing innovative medicines. Founded in 1876 and headquartered in Indianapolis, Indiana, the company operates within the pharmaceuticals and biotechnology sector, addressing a wide spectrum of diseases through prescription drugs and biopharmaceutical products. Eli Lilly’s research and development efforts have produced treatments in areas such as oncology, endocrinology (notably diabetes care), immunology, neuroscience, and rare diseases, making it a key player in improving patient outcomes across multiple therapeutic segments. The company's large scale is reflected in its substantial market capitalization, its listing on major exchanges, and its presence in over 120 countries. Eli Lilly’s continued investment in clinical research and strategic collaborations underscores its pivotal role in driving advancements within the pharmaceutical industry, impacting both healthcare systems and patients worldwide.

CEO
Mr. David A. Ricks
Employees
47,000
Website
lilly.com

Company Statistics

Valuation

P/E
55.2x
P/B
42.94x
P/S
17.48x
EV/EBITDA
33.5x
P/FCF
191.1x

Margins

Gross
83.0%
EBITDA
53.8%
Operating
45.6%
Pre-Tax
39.5%
Net
31.7%

Returns

ROA
21.6%
ROE
101.4%
ROIC
31.1%

Growth (CAGR)

Rev 3Yr
31.7%
Rev 5Yr
21.6%
Op Inc 3Yr
50.8%
Net Inc 3Yr
49.0%

Financial Health

Cash & Cash Equivalents
$7.27B
Net Debt
$78.67B
Debt/Equity
323.9%
Interest Cov
—

Profile

Revenue
$65.18B
Shares Out
—
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Eli Lilly and Company (LLY) Stock Forecast 2026 $1,273.46 — Price, Financials & Analyst Targets | AlphaLenz